Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review
Open accessThe DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Abstract
Patients diagnosed with Neuroendocrine Tumors (NET) often are also diagnosed with Neuroendocrine Liver Metastases (NLM) during the course of their disease. NLM can cause significant morbidity and mortality, oftentimes much more than compared to patients with NET. Treatment options have been limited in the past, focusing on surgical resections, for which only a minority of patients are candidates. However, developments of new treatment modalities have progressed rapidly and patients with NLM now have significantly more options, including surgical-directed therapies; liver-directed therapies; and nonsurgical, non-liver-directed therapies. This review provides information about the roles of hepatic resection, orthotopic liver resection, radiofrequency ablation, hepatic artery embolization and hepatic artery chemoembolization, hepatic artery radioembolization and selective internal radiation therapy, peptide receptor radionuclide therapy, systemic chemotherapy, biotherapies including somatostatin analogs and interferon-α, vascular endothelial growth factor and mTOR targets, and microRNA-regulated pathways. Given these new options, the clinician can tailor therapy specific to the patient diagnosed with NLM, thereby giving the patient the best possible chance of prolonged survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These cases highlight instances where PRRT achieved remarkable therapeutic responses, demonstrating its efficacy by delivering targeted radiation to NET cells while sparing healthy tissues [102].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590 · cited 1×
“Newer positron emission tomography (PET) imaging platforms such as 68Gallium-DOTA0Tyr3octreotide-PET and 68Gallium-DOTA0Tyr3octreotate-PET are increasingly used to evaluate tumors as they are even more sensitive to radiotracer uptake [40] and may be able to better predict responsiveness to PRRT…”
BackgroundEverolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567 · cited 1×
“The more the tumor expresses somatostatin receptors as compared to the surrounding tissue, the more effective the PRRT will be.”
BackgroundRinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456 · cited 1×
“In one study with 310 patients, median overall survival rate from initiation of PRRT was 46 months [47].”
BackgroundDisrupting the Pairing Between let-7 and Hmga2 Enhances Oncogenic Transformation
Mayr, C., Hemann, M. T., & Bartel, D. P. (2007) · Science · doi:10.1126/science.1137999 · Cited by 1,100
Treatment of the Malignant Carcinoid Syndrome
Kvols, L. K., Moertel, C. G., O'Connell, M. J., Schutt, A. J., Rubin, J., & Hahn, R. G. (1986) · New England Journal of Medicine · doi:10.1056/nejm198609113151102 · Cited by 849 · cited 2×
“to a longer half-life of approximately two hours [61].”
BackgroundMoertel, C. G., Kvols, L. K., O'Connell, M. J., & Rubin, J. (1991) · Cancer · doi:10.1002/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i · Cited by 840 · cited 1×
“…fewer nodular liver metastatic lesions, local resection or thermal ablation is recommended; for a higher-tumor load due to unresectable multinodular disease or recurrent disease after resection, hepatic artery embolization, hepatic artery chemoembolization, or radioembolization is warranted [19].”
BackgroundMicroRNA expression and function in cancer
Garzon, R., Fabbri, M., Cimmino, A., Calin, G. A., & Croce, C. M. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.10.006 · Cited by 780 · cited 1×
“Newer positron emission tomography (PET) imaging platforms such as 68Gallium-DOTA0Tyr3octreotide-PET and 68Gallium-DOTA0Tyr3octreotate-PET are increasingly used to evaluate tumors as they are even more sensitive to radiotracer uptake [40] and may be able to better predict responsiveness to PRRT…”
BackgroundStrosberg, J. R., Fine, R. L., Choi, J., Nasir, A., Coppola, D., Chen, D., Helm, J., & Kvols, L. (2011) · Cancer · doi:10.1002/cncr.25425 · Cited by 766 · cited 1×
“temozolomide and thalidomide showed a response rate of 45% [52], and a retrospective study of temozolomide and capecitabine showed a response rate of 70%, a median PFS of 18 months, and an overall 2-year survival of 92% [53].”
Background
Research works printed but not linked: 21
- 2009, 96, 175
- 1990, 108, 1091
- 1998, 66, 1307
- 2002, 73, 386
- 1996, 62, 724
- 2007, 26, 861
- 2011, 18, 127
- 1999, 81, 1351
- 1985, 253, 2741
- 1986, 315, 663
- 1998, 77, 632
- 1991, 30, 503
- 1993, 72, 244
- 1993, 32, 225
- 10.1002/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0 · doi:10.1002/(sici)1097-0142(20000215)88:4<770::aid-cncr6>3.0.co;2-0
- 1991, 23, 2197
- 2009, 31, 169
- 1990, 26, 62
- 2000, 118, 735
- 1999, 84, 3336
- 1996, 57, 84
Cited by
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Oronsky, B., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.002 · Cited by 763
“Another option with neuroendocrine liver lesions, given that the majority of them are hypervascular, is hepatic directed procedures, which include ablative therapy, transarterial embolization, transarterial chemoembolization, and selective internal radiation therapy with yttrium-90 microspheres.(117) Systemic, i.”
BackgroundIto, T., Igarashi, H., Uehara, H., Berna, M. J., & Jensen, R. T. (2013) · Medicine · doi:10.1097/md.0b013e3182954af1 · Cited by 217
Gastroenteropancreatic Neuroendocrine Tumors: Role of Imaging in Diagnosis and Management
Sahani, D. V., Bonaffini, P. A., Fernández–Del Castillo, C., & Blake, M. A. (2013) · Radiology · doi:10.1148/radiol.12112512 · Cited by 191
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144
“These cases highlight instances where PRRT achieved remarkable therapeutic responses, demonstrating its efficacy by delivering targeted radiation to NET cells while sparing healthy tissues [102].”
BackgroundTherapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances
Ito, T., Igarashi, H., & Jensen, R. T. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0642-8 · Cited by 124
“debulking surgery is not recommended where resection cannot be complete or cannot result in the removal of [90 % of the metastatic tumor, because studies show this does not result in improved survival compared with that in patients who do not undergo debulking surgery [21, 25, 26, 98, 101, 102].”
InfluentialTreatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies
Ito, T., Lee, L., & Jensen, R. T. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1236916 · Cited by 98
Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas
González-Vela, M. D. C., Curiel‐Olmo, S., Derdak, S. V., Beltrán, S., Santibáñez, M., Martínez, N., Trujillo, O. A. C., Gut, M., Sánchez-Pacheco, R. E., Almaráz, C., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.08.015 · Cited by 99
“Current treatment options mainly rely on surgical excision combined with loco-regional adjuvant radiation (Harring et al., 2011).”
BackgroundIto, T., Igarashi, H., & Jensen, R. T. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328365efb1 · Cited by 84
Yang, T. X., Chua, T. C., & Morris, D. L. (2012) · Surgical Oncology · doi:10.1016/j.suronc.2012.07.001 · Cited by 82
“While the principle use of somatostatin analogues is to relieve symptoms of NET and NETLMs, recent reviews have shown its use produces both biochemical, clinical and radiological response [4,82].”
BackgroundNeuroendocrine Liver Metastases and Orthotopic Liver Transplantation: The US Experience
Galván, N. T. N., Harring, T. R., Goss, J. A., & O'Mahony, C. A. (2011) · International Journal of Hepatology · doi:10.4061/2011/742890 · Cited by 78
“Because of the higher recurrence rate of NET, these techniques are better considered debulking modalities than curative therapy [22].”
BackgroundSelf-citationManagement of Diarrhea in Patients With Carcinoid Syndrome
Naraev, B. G., Halland, M., Halperin, D. M., Purvis, A. J., O’Dorisio, T. M., & Halfdanarson, T. R. (2019) · Pancreas · doi:10.1097/mpa.0000000000001384 · Cited by 44
Engelman, E. S., Leon-Ferre, R. A., Naraev, B. G., Sharma, N., Sun, S., O’Dorisio, T. M., Howe, J. R., Button, A. M., Zamba, G. K. D., & Halfdanarson, T. R. (2014) · Pancreas · doi:10.1097/mpa.0000000000000030 · Cited by 40
“Surgical interventions for neuroendocrine liver metastases have been shown to have improved outcomes compared with nonsurgical approaches; however, surgery is an option for only a small percentage of patients with liver involvement.(12) Recently, there has been a significant evolution in the management of patients wit…”
BackgroundTherapy for metastatic pancreatic neuroendocrine tumors.
Rossi, R. E., Massironi, S., Conte, D., & PERACCHI, M. (2014) · PubMed · doi:10.3978/j.issn.2305-5839.2013.03.01 · Cited by 39
“Otherwise, according to available data, debulking surgery is not usually performed because a significant improvement in survival has not been reported (8,27).”
BackgroundInfluentialOutcomes of laparoscopic and open resection for neuroendocrine liver metastases
Kandil, E. H., Noureldine, S. I., Koffron, A. J., Lu, Y. W., Saggi, B. H., & Buell, J. F. (2012) · Surgery · doi:10.1016/j.surg.2012.08.027 · Cited by 32
“These factors may in themselves affect surgical decision, raising the threshold for operative intervention favoring the use of less invasive approaches, such as chemoembolization or yttrium.(16,26) Laparoscopic liver resection was introduced for the management of small peripheral tumors of the liver.”
BackgroundKim, S. H., Kim, S. H., Kim, M., Shin, C., Han, J. K., & Choi, B. I. (2015) · European Radiology · doi:10.1007/s00330-015-3600-z · Cited by 28
Hepatic metastatic disease in pediatric and adolescent solid tumors
Fernández‐Pineda, I., Sandoval, J. A., & Davidoff, A. M. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i14.1807 · Cited by 28
Liver Transplantation for Neuroendocrine Tumors: What Have We Learned?
Lim, C., Lahat, E., Osseis, M., Sotirov, D., Salloum, C., & Azoulay, D. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1669936 · Cited by 25
Systemic treatment for lung carcinoids: from bench to bedside
Torniai, M., Scortichini, L., Tronconi, F., Rubini, C., Morgese, F., Rinaldi, S., Mazzanti, P., & Berardi, R. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0238-5 · Cited by 25
“Other options for liver lesions are hepatic directed procedures such as ablative therapy, transarterial embolization, transarterial chemoembolization and selective internal radiation therapy [38].”
BackgroundPerrodin, S. F., Renzulli, M. M., Maurer, M. H., Kim‐Fuchs, C., Candinas, D., Beldi, G., & Lachenmayer, A. (2019) · Endocrine Practice · doi:10.4158/ep-2019-0394 · Cited by 23
Outcome and CT differentiation of gallbladder neuroendocrine tumours from adenocarcinomas
Kim, T., Kim, S. H., Lee, K. B., & Han, J. K. (2016) · European Radiology · doi:10.1007/s00330-016-4394-3 · Cited by 23
Dong, C., Zhao, H., Yang, S., Shi, J., Huang, J., Cui, L., Zhong, L., Jin, X., Li, F., Liu, Z., et al. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400040z · Cited by 23
Progress in Endocrine Neoplasia
Wells, S. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0384 · Cited by 24
Surgical treatment of liver metastases in patients with neuroendocrine tumors.
Saeed, A., Buell, J. F., & Kandil, E. H. (2013) · PubMed Central · doi:10.3978/j.issn.2305-5839.2013.01.08 · Cited by 20
“This might explain the trend toward less invasive approaches to metastatic liver NET tumors such as arterial embolization (28,29).”
BackgroundHamiditabar, M., Muzammil, A., Bolek, L., Vahdati, G., Tworowska, I., & Delpassand, E. S. (2017) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001818 · Cited by 20
A population-based study of outcomes in patients with gastrointestinal neuroendocrine tumours
McMullen, T. P. W., Aljahdali, A. H., de Gara, C., Ghosh, S., McEwan, A. J. B., & Schiller, D. (2017) · Canadian Journal of Surgery · doi:10.1503/cjs.007616 · Cited by 19
Raymond, L. M., Korzun, T., Kardosh, A., Kolbeck, K. J., Pommier, R. F., & Mittra, E. (2021) · Neuroendocrinology · doi:10.1159/000516015 · Cited by 17
Zerbi, A., Capitanio, V., Boninsegna, L., Fave, G. D., Pasquali, C., Rindi, G., Campana, D., & Falconi, M. (2013) · HPB · doi:10.1111/hpb.12065 · Cited by 17
Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art
Tabaksblat, E. M., Langer, S. W., Knigge, U., Grønbæk, H., Mortensen, J., Petersen, R. H., Federspiel, B., & Ladekarl, M. B. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1067715 · Cited by 17
Catheter-Based Treatments for Hepatic Metastases From Neuroendocrine Tumors
Kolbeck, K. J., & Farsad, K. (2014) · American Journal of Roentgenology · doi:10.2214/ajr.14.12983 · Cited by 16
“Like most malignancies, a variety of treatment options exist for neuroendocrine tumors including surgical therapies, systemic chemotherapies, and local-regional treatments dedicated to treating hepatic metastases [6–12].”
BackgroundThe surgical management of neuroendocrine tumour hepatic metastases
Pathak, S., Dash, I., Taylor, M. R., & Poston, G. J. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2012.12.001 · Cited by 14
Multimodality Imaging of the Pancreatic Neuroendocrine Tumors
Singh, A., Hines, J. J., Jr., & Friedman, B. (2019) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2019.04.005 · Cited by 14
MRI-guided laser ablation of neuroendocrine tumor hepatic metastases
Perälä, J. M., Klemola, R., Kallio, R., Li, C., Vihriälä, I., Salmela, P. I., Tervonen, O. A., & Sequeiros, R. T. B. (2014) · Acta Radiologica Open · doi:10.1177/2047981613499753 · Cited by 13
“These therapies include somatostatin analogs, proton pump inhibitors, systemic peptide receptor radionuclide therapy ((131)I-mIBG, (90)Y-DOTATOC, (90)Y-DOTATATE, (177)Lu-DOTATATE), chemotherapy, interferon-a, targeting vascular endothelial growth factors (sunitib), targeting mTOR pathway and micro RNA-regulated pathwa…”
BackgroundRecent advances in the diagnosis and management of pancreatic neuroendocrine tumours
Hopper, A. D., Jalal, M., & Munir, A. (2018) · Frontline Gastroenterology · doi:10.1136/flgastro-2018-101006 · Cited by 16
Pediatric Neuroendocrine Neoplasms: Rare Malignancies with Incredible Variability
Castle, J. T., Levy, B. E., & Chauhan, A. (2022) · Cancers · doi:10.3390/cancers14205049 · Cited by 14
“Hepatic metastases can also be managed with transarterial embolization (bland, radiation, or chemotherapeutic), selective internal radiation, or ablation [124,126].”
BackgroundMultidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas
Folkert, I. W., Hernandez, P. T., & Roses, R. E. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i11.3105 · Cited by 10
Large Cell Neuroendocrine Carcinoma of the Ampulla of Vater
Beggs, R. E., Kelly, M. E., Tayeb, O. E., Crotty, P. L., McDermott, R., & Ridgway, P. F. (2012) · PubMed · doi:10.6092/1590-8577/821 · Cited by 9
“Unfortunately only a small number of patients with metastatic neuroendocrine tumours are suitable surgical candidates [28].”
BackgroundPancreatic neuroendocrine tumors
Shrikhande, S. V., Sirohi, B., Goel, M., & Barreto, S. G. (2012) · Indian Journal of Gastroenterology · doi:10.1007/s12664-012-0257-2 · Cited by 7
Liver transplantation in patients with liver metastases from neuroendocrine tumors
Spolverato, G., Bagante, F., Tsilimigras, D. I., & Pawlik, T. M. (2019) · Minerva Chirurgica · doi:10.23736/s0026-4733.19.08119-7 · Cited by 6
The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012
Macedo, D., Amaral, T. M. S., Fernandes, I., Sousa, A. R., Costa, A. L., Távora, I., Quintela, A., Cortes, P., & Costa, L. (2013) · ISRN Hepatology · doi:10.1155/2013/702167 · Cited by 6
“Therapeutic options for patients without surgical indication have been improved in the latest years [12].”
BackgroundResultInfluentialFard, N., Schlemmer, H., Raue, F., & Jobke, B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212865 · Cited by 7
Filippi, L., Cianni, R., Schillaci, O., & Bagni, O. (2019) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/1573405615666190114150038 · Cited by 5
Liver-Directed Therapies for Neuroendocrine Metastases
Alexander, E. S., & Soulen, M. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-91977-5_21 · Cited by 4
Diffuse Bone Metastases in Pancreatic Neuroendocrine Tumor Shown on Octreoscan
Adkins, J., & Lu, Y. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002455 · Cited by 4
Metastatic carcinoid: Don't forget the surgical consultation
Kelz, R. R., & Fraker, D. L. (2014) · Surgery · doi:10.1016/j.surg.2014.08.086 · Cited by 4
Lebertransplantation bei primären Lebertumoren und Lebermetastasen
Bernsmeier, A., & Braun, F. (2019) · Die Gastroenterologie · doi:10.1007/s11377-019-0352-3 · Cited by 3
Kyriacou, A., Mansoor, W., Lawrance, J., & Trainer, P. J. (2016) · HORMONES · doi:10.1007/bf03401411 · Cited by 3
Jensen, R. T. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch57 · Cited by 4
Three decades of survival in Pancreatic Neuroendocrine Tumor with Unresectable Liver Metastases
Sreevathsa, M. R. (2018) · Annals of Pancreatic Disorders and Treatment · doi:10.17352/apdt.000005 · Cited by 2
Kan, J., Tian, Y., Shao, Y., Xu, H., Li, X., & Tang, Q. (2021) · Tumori Journal · doi:10.1177/03008916211002272 · Cited by 2
Tumor neuroendócrino pancreático com apresentação exuberante – a propósito de um caso
Sousa, N., Soares, P. H. D. S., Monteiro, J., Carvalho, L., Moradi, B., & Ribeiro, J. P. (2016) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.1016/j.rpedm.2016.02.007 · Cited by 2
“A raridade da síndrome carcinoide, associada a este TNE do pâncreas com uma apresentac¸ ão exuberante, torna perti-nente a divulgac¸ ão deste caso A sobreproduc¸ ão hormonal, a multiplicidade de lesões hepáticas e o compromisso da func¸ ão hepática agravam o prognóstico 5 .”
Kyriacou, A., Mansoor, W., Lawrance, J., & Trainer, P. J. (2015) · HORMONES · doi:10.14310/horm.2002.1607 · Cited by 2
Uncommon Cancers of the Stomach
Popa, E., Schnoll‐Sussman, F. H., Jesudian, A. B., Nandakumar, G., & Shah, M. A. (2012) · Wiley eBooks · doi:10.1002/9781118464557.ch28 · Cited by 2
Molecular Imaging and Therapy of Neuroendocrine Tumors
Muzahir, S., & Grady, E. E. (2023) · Exon Publications eBooks · doi:10.36255/molecular-imaging-therapy-endocrine-tumors · Cited by 1
MELD: Which Patients Fall Through the Cracks?
Deising, A. C., & Satoskar, R. S. (2014) · Current Hepatology Reports · doi:10.1007/s11901-014-0211-0 · Cited by 1
An Overview of the Surgical Management of Hepatic Neuroendocrine Metastases
Pathak, S., Dash, I., Taylor, M. R., & Poston, G. J. (2012) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-012-0133-7 · Cited by 1
“option for young patients who fit into the following criteria [9];”
InfluentialAblative Therapies of the Liver and Bone in Medullary Thyroid Cancer
Pasieka, J. L., & Harvey, A. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-39412-1_16 · Cited by 1
Imaging for Interventional Radiology Liver-Directed Therapies for Neuroendocrine Liver Metastases
Kumari, D., de Bruyn, E., & Al-Qawasmi, F. (2024) · Seminars in Interventional Radiology · doi:10.1055/s-0044-1788338 · Cited by 1
Surgical strategy for neuroendocrine liver metastases
Fung, A. K. Y., & Chong, C. C. N. (2019) · Surgical Practice · doi:10.1111/1744-1633.12364 · Cited by 1
“If debulking hepatectomy cannot achieve the above target, there is no survival benefit compared to non-operative management.(50,51) Debulking hepatec-”
BackgroundBiology of Liver Tumors and Outcomes of Liver Surgery
Kontis, E. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-51331-3_18 · Cited by 1
Ligand-Directed AAVP to Deliver a Therapeutic Transgene to Neuroendocrine Tumors of the Pancreas
Smith, T. L. (2013) · Digital Commons-TMC (Texas Medical Center)
Liver Transplantation For Neuroendocrine Tumors: Review of the Literature and Future Perspectives
Wurst, C., Jandt, K., Schuele, S., Rauchfuß, F., & Settmacher, U. (2014) · International Journal of Endocrine Oncology · doi:10.2217/ije.14.8
The Clinical Challenge of Liver Metastasis
Cappato, S., Brena, F., Squadroni, M., Barile, R., Piccinali, D., Mancin, A., Quartierini, G., Goletti, O., & Beretta, G. D. (2018) · Springer eBooks · doi:10.1007/978-3-319-63067-0_14
Resection Versus Chemotherapy for Metastatic Neuroendocrine Tumors of the Pancreas
Christians, K. K., Younan, G. J., George, B., Tsai, S., & Evans, D. B. (2018) · Difficult decisions in surgery: an evidence-based approach · doi:10.1007/978-3-319-92860-9_36
Tektrotyd scan showing a diffuse bone metastasis in patient with a neuroendocrine pancreatic tumor
Sellem, A., Mahjoub, Y., Elajmi, W., & Hammami, H. (2020) · Indian Journal of Nuclear Medicine · doi:10.4103/ijnm.ijnm_17_20
Palliative Interventions for Metastatic Neuroendocrine Tumors
Hodge, C., & Fahy, B. N. (2021) · Springer eBooks · doi:10.1007/978-3-030-62241-1_19
Orsi, F., & Bonomo, G. (2021) · Springer eBooks · doi:10.1007/978-3-030-72830-4_10
Tunçer, A., Ogut, M. Z., Usta, S., Akbulut, S., Şahin, T. T., & Yılmaz, S. (2021) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-021-00719-6
Uncommon Cancers of the Stomach
Popa, E., Schnoll‐Sussman, F. H., Jesudian, A. B., Nandakumar, G., & Shah, M. A. (2017) · Wiley eBooks · doi:10.1002/9781119196235.ch27
Tunçer, A., Ogut, M. Z., Usta, S., Akbulut, S., Şahin, T. T., & Yılmaz, S. (2021) · Research Square · doi:10.21203/rs.3.rs-921335/v1
Metadata
- Authors
- Harring, T. R., Nguyen, N. T. N., Goss, J. A., & O'Mahony, C. A.
- Affiliations
- Baylor College of Medicine (US)
- Corresponding author
- O'Mahony, Christine A.
- Venue
- International Journal of Hepatology
- Publisher
- Wiley
- Published
- 2011
- Volume
- 2011
- Pages
- 1-11
- ISSN
- 2090-3448 (ISSN-L)
- 2090-3456
- PMC
- PMC3195553
- OpenAlex
- W2108019032
- Cited by
- 69
- References
- 103
- Citations by year
- 2024: 2 · 2023: 1 · 2022: 1 · 2021: 6 · 2020: 2 · 2019: 10 · 2018: 6 · 2017: 4 · 2016: 8 · 2015: 5 · 2014: 7 · 2013: 8 · 2012: 8
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- International Journal of Hepatology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- neuroendocrine liver metastases, neuroendocrine tumors, hepatectomy, orthotopic liver transplantation, radiofrequency ablation, hepatic artery embolization, hepatic artery chemoembolization, radioembolization, peptide receptor radionuclide therapy, somatostatin analogues, interferon-alpha, mTOR inhibitors, vascular endothelial growth factor, microRNA, systemic chemotherapy, biologic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
